Chang, Yen-Hwa
2 papers on CoChat
Most cited papers
- Verified
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine
Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers
Cited by 3,403
- Verified
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
Powles, T., Csőszi, T., Özgüroğlu, M., Matsubara, N., Géczi, L., Cheng, S. Y.-S., Fradet, Y., Oudard, S., Vulsteke, C., Morales Barrera, R., et al. (2021) · The Lancet Oncology
Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers
Cited by 643
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free